Syntara (SNT) Stock Overview
Operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SNT Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.029 |
| 52 Week High | AU$0.089 |
| 52 Week Low | AU$0.023 |
| Beta | 0.23 |
| 1 Month Change | -17.14% |
| 3 Month Change | -12.12% |
| 1 Year Change | -62.82% |
| 3 Year Change | -35.56% |
| 5 Year Change | -65.88% |
| Change since IPO | -93.56% |
Recent News & Updates
Recent updates
Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
Nov 28
Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
May 10Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified
Jul 05Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Apr 29Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04
Shareholder Returns
| SNT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -6.5% | -0.9% | -2.7% |
| 1Y | -62.8% | -13.3% | 10.2% |
Return vs Industry: SNT underperformed the Australian Pharmaceuticals industry which returned -11.3% over the past year.
Return vs Market: SNT underperformed the Australian Market which returned 11.1% over the past year.
Price Volatility
| SNT volatility | |
|---|---|
| SNT Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: SNT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: SNT's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 21 | Gary Phillips | syntaratx.com.au |
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for keloid scars; and SNT-4728 to treat sleep disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation.
Syntara Limited Fundamentals Summary
| SNT fundamental statistics | |
|---|---|
| Market cap | AU$47.39m |
| Earnings (TTM) | -AU$13.16m |
| Revenue (TTM) | AU$7.50m |
Is SNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNT income statement (TTM) | |
|---|---|
| Revenue | AU$7.50m |
| Cost of Revenue | AU$11.36m |
| Gross Profit | -AU$3.86m |
| Other Expenses | AU$9.30m |
| Earnings | -AU$13.16m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0081 |
| Gross Margin | -51.45% |
| Net Profit Margin | -175.46% |
| Debt/Equity Ratio | 0% |
How did SNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 15:48 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Syntara Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Madeleine Williams | Canaccord Genuity |